Synthon acquires Syntarga and its Antibody-Drug Conjugate Technology
28-Jun-2011 -
Synthon announced its acquisition of Syntarga BV. Syntarga’s activities are focused on the development of innovative chemistries that arm antibodies with a cytotoxic payload - yielding successful Antibody-Drug Conjugate (ADC) products that specifically target and kill cancer cells.“Through this ...
antibodies
antibody-drug conjugate
cancer